-
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS
Monday, June 20, 2011 - 2:21am | 138Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of earnings per share. The trailing-twelve-month earnings per share at Trinity Biotech plc (NASDAQ: TRIB) is $2.78. TRIB's ROE for the same period is 53.87%. The trailing-twelve-month earnings per share...
-
Merit Medical Systems Falling On Offering
Friday, June 17, 2011 - 1:21pm | 128Merit Medical Systems, Inc. (NASDAQ: MMSI) shares are falling sharply on heavy volume, down more than 3%, as the company priced a secondary offering this morning at $16.75 per share. Shares are much higher than that level, trading at $17.97, as the company sold 4.8 million shares in the offering....
-
Last Nights Noteables, Upgrades Downgrades of Note
Friday, June 17, 2011 - 9:23am | 294GenMark Diagnostics, Inc. (GNMK) offering of 7,065,600 shares of its common stock at a price to the publicof $4.25 per 8:30a (T3) Tim_K: Merit Medical (MMSI) Offering Mitchum Industries (MIND) offering - Hearing its coming at 15 - Stong daily overall. trading 15.25 post market down $1.22...
-
Merit Medical Systems, Inc. Announces Commencement of Public Offering of Common Stock
Thursday, June 16, 2011 - 4:00pm | 155Merit Medical Systems, Inc. (Nasdaq: MMSI) today announced that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. is acting as the sole manager for the offering. Merit expects to use the net proceeds from the offering to partially repay debt under its...
-
Jefferies Comments On ViroPharma's Cinryze Approval In Europe
Thursday, June 16, 2011 - 8:03am | 116According to Jefferies, VitoPharma (NASDAQ: VPHM) announced that the European Medicines Agency approved Cinryze in Europe for the treatment of hereditary angioedema (HAE). Jefferies said that it remains confident in $400m+ U.S. Cinryze prophylactic HAE sales by 2015. “Cetor is only selling in a...
-
ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema
Wednesday, June 15, 2011 - 10:33am | 142ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission has granted ViroPharma Centralized Marketing Authorization for Cinryze® (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema (HAE) for routine prevention, pre-procedure prevention and acute...
-
Endologix Announces FDA Approval of AFX Endovascular AAA System
Wednesday, June 15, 2011 - 9:01am | 65Endologix, Inc. (Nasdaq: ELGX) announced today that it has received U.S. Food and Drug Administration approval for its next generation product, the AFX™ Endovascular AAA System, for the treatment of abdominal aortic aneurysms . Endologix is introducing AFX at the Annual Meeting of the Society...
-
Morgan Keegan Adjusts Cooper Companies Estimates
Friday, June 10, 2011 - 8:17am | 51Morgan Keegan is adjusting its estimates on The Cooper Companies (NYSE: COO) to “account for lower interest expense as our previous assumption now appears too conservative.” “We have increased our 2012 EPS estimate to $4.60 from $4.55,” Morgan Keegan writes. The Cooper Companies closed Thursday...
-
Cerus Corporation and Ilex Biotech LTD Initiate Distribution Agreements for the INTERCEPT Blood System in South Africa and Israel
Thursday, June 9, 2011 - 7:03am | 165Cerus Corporation (NASDAQ: CERS) today announced today that it has entered into agreements with Ilex Biotech Limited to distribute Cerus' INTERCEPT Blood System for platelets and plasma in South Africa and Israel. The INTERCEPT Blood System is designed to provide increased protection from a broad...
-
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROE
Tuesday, June 7, 2011 - 1:41am | 139Below are the top small-cap diagnostic substances stocks on the NYSE, the NASDAQ and the AMEX in terms of return on equity. The trailing-twelve-month return on equity at Trinity Biotech plc (NASDAQ: TRIB) is 53.87%. TRIB's PEG ratio is 0.94. The trailing-twelve-month return on equity at Accelr8...
-
6 Stocks That Are Gaining Momentum
Monday, June 6, 2011 - 2:47pm | 200This is a stock screen similar to "Stocks That Are Breaking Down" (but just the exact opposite). A lot of these stocks are positioned for breakouts in the near future. If you are a momentum trader, you have to take a look at the charts of each of these stocks listed below. Each of the stocks below...
-
Neogen's BetaStar Plus Dairy Antibiotic Test Approved by FDA/NCIMS
Monday, June 6, 2011 - 8:45am | 216Neogen Corporation (NASDAQ: NEOG) has received approval from the FDA and National Conference on Interstate Milk Shipments for its quick and easy BetaStar Plus assay, developed for use in the United States to detect dairy antibiotic residues, including ceftiofur, in milk. This approval allows milk...
-
Richard J. Meelia Elected Chairman of Haemonetics Board of Directors
Monday, June 6, 2011 - 8:10am | 185Haemonetics Corporation (NYSE: HAE) announced today that its Board of Directors elected Rich Meelia to join the Board and assume the role of Chairman, effective immediately. Meelia, 62, will retire as Covidien plc's President and Chief Executive Officer on July 1, 2011. He will remain as Non-...
-
Benchmark Maintains Buy on Synergetics USA
Monday, June 6, 2011 - 8:01am | 121Deutsche Bank is out with its report today on Synergetics USA (NASDAQ: SURG), maintaining Buy. In a note to clients, Deutsche Bank writes, "In F2012 we forecast 50% EPS expansion to $0.33. That implies a 16x PE multiple for what becomes the current fiscal year in just two months (August). Based on...
-
Options Brief: Immucor, Inc.
Friday, June 3, 2011 - 3:17pm | 85Shares of Immucor, Inc. (NASDAQ: BLUD) are lower on the session by 2.09%, trading at $20.12. Overall put volume is now running at 72.30x the daily average, with 79% of all puts traded being purchases on the offer. 1,446 contracts have traded on the session so far. Immucor, Inc. develops,...